Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
1. A multiparticulate controlled release formulation comprising:
i) an immediate release component comprising levodopa, esters or salts thereof and a decarboxylase inhibitor,
ii) and a controlled release component comprising a core comprising levodopa, esters or salts thereof, and
wherein the immediate release component comprises from about 80% to about 100% of the total amount of decarboxylase inhibitor in the multiparticulate controlled release formulation and wherein the controlled release component is free of the decarboxylase inhibitor.
2. The multiparticulate controlled release formulation of claim 1 , wherein the controlled release component further comprises a mucoadhesive coating over the core.
3. The multiparticulate controlled release formulation of claim 2 , wherein the controlled release component further comprises a controlled release coating which undercoats the mucoadhesive coating.
4. The multiparticulate controlled release formulation of claim 3 , wherein the controlled release coating comprises a controlled release material selected from the group consisting of ethyl cellulose, cellulose acetate, and mixtures thereof.
5. The multiparticulate controlled release formulation of claim 2 , wherein the mucoadhesive coating comprises a mucoadhesive polymer that is capable of forming a positive ionic charge at the pHs present in the human gastrointestinal tract.
6. The multiparticulate controlled release formulation of claim 5 , wherein the mucoadhesive polymer is amino methacrylate copolymer.
7. The controlled release formulation of claim 6 , wherein the amino methacrylate copolymer is a poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methylmethacrylate).
8. The multiparticulate controlled release formulation of claim 2 , wherein the formulation further comprises a coating comprising an enteric material surrounding the mucoadhesive coating.
9. The multiparticulate controlled release formulation of claim 1 , wherein the controlled release component passes through mesh screen number 16.
10. The multiparticulate controlled release formulation of claim 1 , wherein the controlled release component is retained on mesh screen number 18.
11. A multiparticulate controlled release formulation comprising:
i) an immediate release component comprising levodopa, esters or salts thereof and a decarboxylase inhibitor, and
ii) a controlled release component comprising a core comprising levodopa, esters or salts thereof,
wherein the immediate release component comprises from about 80% to about 100% of the total amount of decarboxylase inhibitor in the multiparticulate controlled release formulation and wherein the controlled release component is s free of the decarboxylase inhibitor,
wherein the formulation on oral administration to a human subject under fasting conditions provides 50% of a maximum levodopa plasma concentration (50% C max ) within one hour of the administration of the formulation and the 50% C max plasma concentration of levodopa is maintained for at least about 3 hours.
12. The multiparticulate controlled release formulation of claim 11 , wherein the 50% C max plasma concentration of levodopa is maintained for at least about 5 hours.
13. A multiparticulate controlled release formulation comprising:
i) an immediate release component comprising granules comprising levodopa, esters or salts thereof and a decarboxylase inhibitor, and
ii) a controlled release component comprising spheronized bead cores comprising levodopa, esters or salts thereof,
wherein the immediate release component comprises from about 80% to about 100% of the total amount of decarboxylase inhibitor in the multiparticulate controlled release formulation and wherein the controlled release component is free of the decarboxylase inhibitor.
14. The multiparticulate controlled release formulation of claim 13 , wherein the controlled release component further comprises a mucoadhesive coating over the spheronized bead core.
15. The multiparticulate controlled release formulation of claim 14 , wherein the controlled release component further comprises a controlled release coating which undercoats the mucoadhesive coating.
16. The multiparticulate controlled release formulation of claim 15 , wherein the controlled release coating comprises a controlled release material selected from the group consisting of ethyl cellulose, cellulose acetate, and mixtures thereof.
17. The multiparticulate controlled release formulation of claim 14 , wherein the mucoadhesive coating comprises a muco-adhesive polymer that is capable of forming a positive ionic charge at the pHs present in the human gastrointestinal tract.
18. A method for treating Parkinson's disease or Primary Parkinsonism in a subject in need of such treatment comprising oral administration of a multiparticulate controlled release formulation comprising:
i) an immediate release component comprising levodopa, esters or salts thereof and a decarboxylase inhibitor, and
ii) a controlled release component comprising a core comprising levodopa, esters or salts thereof, and
wherein the immediate release component comprises from about 80% to about 100% of the total amount of decarboxylase inhibitor in the multiparticulate controlled release formulation and wherein the controlled release component is free of the decarboxylase inhibitor.